Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nemolizumab in Pediatric Subjects With Moderate-to-Severe Atopic Dermatitis
NCT04921345Phase 2Completed
- Sponsor
- Galderma
- Start
- Jun 2021
- Primary completion
- Apr 2025
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of nemolizumab in atopic dermatitis (AD), sponsored by Galderma. Started Jun 2021; status: completed.
02
Drugs
nemolizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04921345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04921345.